Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:43:16.412Z.
Calculation as of: 2026-10-06T16:43:16.412Z.
Quote observation: 2026-10-06T16:35:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
PE RATIO
N/A
Market Cap
$60.99M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $61.77M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.99M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.71M | N/A | 110.41 | 110.41 | 110.41 |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $64.09M | N/A | 45.99 | 45.99 | 45.99 |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.71M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.90M | N/A | 2.96 | 2.96 | 2.96 |
| PDS Biotechnology Corporation (PDSB)vs › | $59.56M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.57M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.83
Forward EPS (Est.)
$-2.01
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
